Skip to main content

Table 1 Baseline demographics and patient characteristics

From: A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Characteristic Number of patients (N = 41)
Age, years
 Median (range) 54 (30–73)
Sex
 Male 1 (2.4%)
 Female 40 (97.6%)
Race
 White 33 (80.5%)
 Black or African American 5 (12.2%)
 Unknown 3 (7.3%)
Ethnicity
 Hispanic or Latino 6 (14.6%)
 Not Hispanic or Latino 30 (73.2%)
 Unknown 5 (12.2%)
ECOG Performance Status
 0 19 (46.3%)
 1 22 (53.7%)
Prior lines of systemic therapy
 (locally advanced unresectable or metastatic disease) Mean 1.7
 1 21 (51.2%)
 2 10 (24.4%)
 3 10 (24.4%)
Prior neoadjuvant or adjuvant chemotherapy
 Yes 33 (80.5%)
 No 8 (19.5%)
Prior targeted systemic anticancer therapy
 Yes 20 (48.8%)
 No 21 (51.2%)
Prior radiation therapy
 Yes 35 (85.4%)
 No 6 (14.6%)
BRCA1/2 germline deleterious mutation status
 Mutated 4 (9.8%)
 Wildtype 19 (46.3%)
 Unknown 18 (43.9%)
Number of metastatic sites
 1 16 (39.0%)
 2 14 (34.1%)
  ≥ 3 11 (26.8%)
Sites of metastasis
 Lung 15 (24.4%)
 Lymph nodes 20 (48.8%)
 Liver 15 (24.4%)
 Bone 16 (39.0%)
 Chest wall 8 (19.5%)
 Other 6 (14.6%)
  1. ECOG Eastern Cooperative Oncology Group